PAR 3.92% 24.5¢ paradigm biopharmaceuticals limited..

Interview with Paul Rennie and Capital 51, page-5

  1. 17 Posts.
    Pricing feedback/analysis due Q3-Q4 CY. So pay for use wont be any earlier than that I would assume?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.